

---

Auszug aus lediglich in „Peer-review“ Fachzeitschriften veröffentlichten Volltext-Publikationen:

1. Sabet A, Dautzenberg K, Haslerud T, Aouf A, Sabet A, Simon B, Mayer K, Biersack HJ, **Ezziddin S**. Specific efficacy of peptide receptor radionuclide therapy with <sup>177</sup>Lu-octreotate in advanced neuroendocrine tumors of the small intestine. *Eur J Nucl Med Mol Imaging*. in press IF<sub>2012</sub>: 5.11
2. Anlauf M, Neumann N, Bomberg S, Luszak K, Heikaus S, Gustmann C, Antke C, **Ezziddin S**, Fottner C, Pavel M, Pape UF, Rinke A, Groh U, Al-Katout I, Rudlowski C, Scheler P, Zirbes TK, Hoffmann J, Fehm T, Gabbert HE, Baldus SE. Neuroendokrine Neoplasien (NEN) der Mamma. *Pathologe* 2015, in press. IF<sub>2012</sub>: 0.62
3. **Ezziddin S**, Adler L, Sabet A, Pöppel TD, Grabellus F, Yüce A, Fischer HP, Simon B, Höller T, Biersack HJ, Nagarajah J. Prognostic stratification of metastatic gastroenteropancreatic neuroendocrine neoplasms by FDG-PET: Feasibility of a metabolic grading system. *J Nucl Med*. in press. IF<sub>2012</sub>: 5.77
4. Anlauf M, Sipos M, Boeck I, Baldus SE, Heikaus S, Krausch M, Knoefel WT, Begum N, Goretzki P, Schott M, Auernhammer CJ, Cremer B, Rinke A, **Ezziddin S**, Fottner C, Pöppel G, Lahner H, Hörsch D, Gabbert HE, Komminoth P, Perren A, Klöppel G, Wiedenmann B, Pavel M, Pape U. Neuroendocrine neoplasms of the distal jejunum and ileum. *Pathologe* 2014, in press. IF<sub>2012</sub>:0.62
5. **Ezziddin S**, Sabet A, Yong-Hing CJ, Biersack HJ. Comment on Campana et al.: Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence. *Eur J Nucl Med Mol Imaging*. 2014;41(1):174-5. IF<sub>2012</sub>: 5.11
6. **Ezziddin S**, Khalaf F, Vanezi M, Haslerud T, Mayer K, Al Zreiqat A, Willinek WA, Biersack HJ, Sabet A. Outcome of PRRT with <sup>177</sup>Lu-octreotate in advanced pancreatic neuroendocrine tumors G1-2. *Eur J Nucl Med Mol Imaging*. 2014;41(5):925-933. IF<sub>2012</sub>: 5.11
7. Sabet A, Yong-Hing CJ, Sabet A, Haslerud T, Guhlke S, Grünwald F, Biersack HJ, **Ezziddin S**. Can peptide receptor radionuclide therapy be safely applied in florid bone metastases? A pilot analysis of late stage osseous involvement. *Nuklearmedizin*. 2014;53(2):54-59. IF<sub>2012</sub>: 1.32
8. **Ezziddin S**, Attassi M, Yong-Hing CJ, Ahmadzadehfar H, Willinek W, Grünwald F, Guhlke S, Biersack HJ, Sabet A. Predictors of long-term outcome in well-differentiated GEP-NET after PRRT with <sup>177</sup>Lu-octreotate. *J Nucl Med*. 2014;55(2):183–190. IF<sub>2012</sub>: 5.77
9. Sabet A, Ezziddin K, Pape UF, Reichman K, Haslerud T, Ahmadzadehfar H, Nagarajah J, Biersack HJ, **Ezziddin S**. Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with <sup>177</sup>Lu-octreotate. *Eur J Nucl Med Mol Imaging*. 2014;41(3):505-510. IF<sub>2012</sub>: 5.11
10. Sabet A, Haslerud T, Pape UF, Sabet A, Ahmadzadehfar H, Grünwald F, Guhlke S, Biersack HJ, **Ezziddin S**. Outcome and toxicity of salvage therapy with <sup>177</sup>Lu-octreotate in patients with metastatic gastroenteropancreatic neuroendocrine tumors. *Eur J Nucl Med Mol Imaging*. 2014;41(2):205-10. IF<sub>2012</sub>: 5.11
11. Kukuk GM, Mürtz P, Träber F, Meyer C, Ullrich J, Gieseke J, Ahmadzadehfar H, **Ezziddin S**, Schild HH, Willinek WA. Diffusion- weighted imaging with acquisition of three b-values for response evaluation of neuroendocrine liver metastases undergoing selective internal radiotherapy. *Eur Radiol*. 2014;24(2):267-76. IF<sub>2012</sub>: 3.55
12. Sabet A, Khalaf F, Mahjoob S, Al-Zreiqat A, Biersack HJ, **Ezziddin S**. May bone-targeted radionuclide therapy overcome PRRT-refractory osseous disease in NET? A pilot report on <sup>188</sup>Re-HEDP treatment in progressive bone metastases after <sup>177</sup>Lu-octreotate. *Am J Nucl Med Mol Imaging*. 2013;4(1):80-8. IF<sub>2012</sub>: -

13. Sabet A, Khalaf F, Haslerud T, Al-Zreiqat A, Sabet A, Simon B, Pöppel TD, Biersack HJ, **Ezziddin S**. Bone metastases in GEP-NET: response and long-term outcome after PRRT from a follow-up analysis. *Am J Nucl Med Mol Imaging*. 2013;3(5):437-445. IF<sub>2012</sub>: -
14. Sabet A, Nagarajah J, Dogan S, Biersack HJ, Sabet A, Guhlke S, **Ezziddin S**. Does PRRT with standard activities of <sup>177</sup>Lu-octreotate really achieve relevant somatostatin receptor saturation in target tumor lesions? Insights from intra-therapeutic receptor imaging in patients with metastatic gastroenteropancreatic neuroendocrine tumors. *EJNMMI Res*. 2013;3(1):82. IF<sub>2012</sub>: -
15. **Ezziddin S**, Sabet A, Logvinski T, Alkawaldeh K, Yong-Hing CJ, Ahmadzadehfar H, Grünwald F, Biersack HJ. Long-term outcome and toxicity after dose-intensified treatment with <sup>131</sup>I-MIBG in advanced metastatic carcinoid tumors. *J Nucl Med*. 2013;54(12):2032-8. IF<sub>2012</sub>: 5.77
16. Sabet A, Ezziddin K, Pape UF, Ahmadzadehfar H, Mayer K, Pöppel TD, Guhlke S, Biersack HJ, **Ezziddin S**. Long-term hematotoxicity after peptide receptor radionuclide therapy with <sup>177</sup>Lu-octreotate. *J Nucl Med*. 2013;54(11):1857-61. IF<sub>2012</sub>: 5.77
17. **Ezziddin S**, Reichmann K, Yong-Hing C, Damm M, Risse J, Ahmadzadehfar H, Logvinski T, Guhlke S, Biersack HJ, Sabet A. Early prediction of tumor response to PRRT - The sequential change of tumor-absorbed doses during treatment with Lu<sup>177</sup>-octreotate. *Nuklearmedizin*. 2013;52(5):170-7. IF<sub>2012</sub>: 1.32
18. **Ezziddin S**, Meyer C, Kohancova S, Haslerud T, Willinek W, Wilhelm K, Biersack HJ, Ahmadzadehfar H. <sup>90</sup>Y Radioembolization After Radiation Exposure from Peptide Receptor Radionuclide Therapy. *J Nucl Med*. 2012;53(11):1663-9. IF<sub>2012</sub>: 5.77
19. Sabet A\*, **Ezziddin S\***, Heinemann H, Guhlke S, Muckle M, Willinek W, Biersack HJ, Ahmadzadehfar H. Diagnostic value of intra-therapeutic <sup>177</sup>Lu-octreotate imaging in osseous metastases of GEP NET: comparison with bone scintigraphy. *Nuklearmedizin*. 2012;51(3):95-100. \*Both authors equally contributed. IF<sub>2012</sub>: 1.32
20. **Ezziddin S**, Lohmar J, Yong-Hing C, Sabet A, Ahmadzadehfar H, Kukuk G, Biersack HJ, Guhlke S, Reichmann K. Does the pretherapeutic tumor SUV in (68)Ga-DOTATOC PET predict the absorbed dose of Lu<sup>177</sup>-octreotate? *Clin Nucl Med*. 2012;37(6):141-7. IF<sub>2012</sub>: 2.96
21. Hörsch D, **Ezziddin S**, Haug A, Gratz KF, Dunkelmann S, Krause BJ, Schümichen C, Bengel FM, Knapp WH, Bartenstein P, Biersack HJ, Plöckinger U, Schwartz-Fuchs S, Baum RP. Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors in Germany: First Results of a Multi-institutional Cancer Registry. *Recent Results Cancer Res*. 2012;194:457-65. IF<sub>2012</sub>: -
22. Begum N, Maasberg S, Plöckinger U, Anlauf M, Rinke A, Pöpperl G, Lehnert H, Izbicki JR, Krausch M, Vashist YK, Raffel A, Bürk CG, Hoffmann J, Goretzki P, Pape UF; other representatives of the German NET Registry. Neuroendocrine Tumours of the GI Tract - Data from the German NET Registry. *Zentralbl Chir*. 2012; Epub. IF<sub>2012</sub>: 0.69
23. Hörsch D, **Ezziddin S**, Haug A, Gratz KF, Dunkelmann S, Krause BJ, Schümichen C, Bengel FM, Knapp WH, Bartenstein P, Biersack HJ, Plöckinger U, Schwartz-Fuchs S, Baum RP. Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors in Germany: First Results of a Multi-institutional Cancer Registry. *Recent Results Cancer Res*. 2012;194:457-65. IF<sub>2012</sub>: -
24. **Ezziddin S**, Sabet A, Ko YD, Xun S, Matthies A, Biersack HJ. Repeated Radionuclide therapy in metastatic paraganglioma leading to the highest reported cumulative activity of <sup>131</sup>I-MIBG. *Radiat Oncol*. 2012;25;7:8. IF<sub>2012</sub>: 2.11
25. **Ezziddin S**, Lauschke H, Schaefers M, Meyer C, Van Essen M, Biersack HJ, Kwekkeboom DJ, Ahmadzadehfar H. Neoadjuvant downsizing by internal radiation: A case for preoperative peptide receptor radionuclide therapy in pancreatic neuroendocrine tumors. *Clin Nucl Med*. 2012;37(1):102-4. IF<sub>2012</sub>: 2.96
26. **Ezziddin S**, Sabet A, Heinemann F, Yong-Hing C, Ahmadzadehfar H, Guhlke S, Höller T, Willinek W, Boy C, Biersack HJ. Response and long-term control of bone metastases after

- 
- peptide receptor radionuclide therapy with  $^{177}\text{Lu}$ -octreotate. *J Nucl Med.* 2011;52(8):1197-203. IF<sub>2012</sub>: 5.77
27. **Ezziddin S**, Opitz M, Attassi M, Biermann K, Sabet A, Guhlke S, Brockmann H, Willinek W, Wardelmann E, Biersack HJ, Ahmadzadehfar H. Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy. *Eur J Nucl Med Mol Imaging.* 2011; 38(3):459-66. IF<sub>2012</sub>: 5.11
  28. Pape UF, Pascher A, Arsenic R, **Ezziddin S**, Jann H, Pavel ME, Wiedenmann B. Gastrointestinal neuroendocrine neoplasias: novel individualized therapeutic strategies. *Dtsch Med Wochenschr.* 2011;136(36):1801-6. IF<sub>2012</sub>:0.65
  29. Grünwald F, **Ezziddin S**.  $^{131}\text{I}$ -metaiodobenzylguanidine therapy of neuroblastoma and other neuroendocrine tumors. *Semin Nucl Med.* 2010;40(2):153-63. IF<sub>2012</sub>:3.82
  30. Ploeckinger U, Kloeppel G, Wiedenmann B, Lohmann R; representatives of 21 German NET Centers. The German NET-registry: an audit on the diagnosis and therapy of neuroendocrine tumors. *Neuroendocrinology.* 2009;90(4):349-63. IF<sub>2012</sub>: 3.54
  31. **Ezziddin S**, Logvinski T, Yong-Hing C, Ahmadzadehfar H, Fischer HP, Palmedo H, Bucerius J, Reinhardt MJ, Biersack HJ. Factors predicting tracer uptake in somatostatin receptor and MIBG Scintigraphy of metastatic gastroenteropancreatic neuroendocrine tumors. *J Nucl Med.* 2006; 47(2):223-33. IF<sub>2012</sub>: 5.77
  32. **Ezziddin S**, Biersack HJ. Nuklearmedizinische Diagnostik und Therapie neuroendokriner Tumore mit MIBG und Somatostatinanaloga. Diagnóstico y Tratamiento por Medicina Nuclear de los Tumores Neuroendocrinos con MIBG y análogos de Somatostatina. *Oncologia Nuclear. de Castro-Beiras JM, Oliva Gonzalez JP (Hrsg), 2006.*
  33. Yüksel M, **Ezziddin S**, Ladwein E, Haas S, Biersack HJ.  $^{111}\text{In}$ -pentetreotide and  $^{123}\text{I}$ -MIBG for detection and resection of lymph node metastases of a carcinoid not visualized by CT, MRI or FDG-PET. *Ann Nucl Med.* 2005; 19(7):611-5. IF<sub>2012</sub>: 1.41
  34. Biersack HJ, **Ezziddin S**, Risse J, Bender H, Palmedo H. Therapy with radioisotopes in oncology. Palliative and curative approaches. *Schmerz.* 2005;19(1):9-17. IF<sub>2012</sub>:1.02
  35. Gao Z, Biersack HJ, **Ezziddin S**, Logvinski T, An R. The role of combined imaging in metastatic medullary thyroid carcinoma:  $^{111}\text{In}$ -DTPA-octreotide and  $^{131}\text{I}/^{123}\text{I}$ -MIBG as predictors for radionuclide therapy. *J Cancer Res Clin Oncol.* 2004;130(11):649-56. IF<sub>2012</sub>: 2.91